Literature DB >> 10759774

Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase.

S Rafati1, A A Baba, M Bakhshayesh, M Vafa.   

Abstract

Cellular immune mechanisms resulting in interferon-gamma (IFN-gamma) production are essential for protection against cutaneous leishmaniasis. Antigens of the intracellular amastigote form of the parasite, found in mammalian hosts, are likely to be good candidates for the induction of T cell response and protection from development of leishmaniasis. We purified a stage-specific antigen from amastigote soluble antigen (A-SLA) of Leishmania major by immunoaffinity chromatography. The purified protein was characterized as a cysteine proteinase with enzymatic activity which is inhibited by E-64, and it was named the amastigote cysteine proteinase (ACP). BALB/c mice were immunized by two intraperitoneal injections, at a month interval, of 5 microg of ACP or A-SLA in Freund's complete adjuvant (FCA). Animals were challenged 4 weeks later with 106 L. major promastigotes and examined 4 months after the last injection. The immunized animals developed significantly smaller or no lesions compared with controls. Spleen cells from immunized mice showed a significant proliferative response and produced a high level of IFN-gamma in response to ACP, suggesting the induction of Th1 cells after immunization. These results make 24-kD ACP a possible component for an eventual cocktail vaccine against L. major infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759774      PMCID: PMC1905606          DOI: 10.1046/j.1365-2249.2000.01160.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Leishmania major and L. donovani: a method for rapid purification of amastigotes.

Authors:  T A Glaser; S J Wells; T W Spithill; J M Pettitt; D C Humphris; A J Mukkada
Journal:  Exp Parasitol       Date:  1990-10       Impact factor: 2.011

Review 2.  T-cell responses and immunity to experimental infection with leishmania major.

Authors:  I Müller; T Pedrazzini; J P Farrell; J Louis
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

Review 3.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

4.  The characterization of four monoclonal antibodies specific for mouse IL-5 and development of mouse and human IL-5 enzyme-linked immunosorbent.

Authors:  J H Schumacher; A O'Garra; B Shrader; A van Kimmenade; M W Bond; T R Mosmann; R L Coffman
Journal:  J Immunol       Date:  1988-09-01       Impact factor: 5.422

5.  Long-term protection of mice against Leishmania major with a synthetic peptide vaccine.

Authors:  N Spitzer; A Jardim; D Lippert; R W Olafson
Journal:  Vaccine       Date:  1999-03-17       Impact factor: 3.641

6.  Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay.

Authors:  T R Mosmann; J H Schumacher; D F Fiorentino; J Leverah; K W Moore; M W Bond
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

7.  Production of interferon-gamma during infection of mice with Plasmodium chabaudi chabaudi.

Authors:  S J Slade; J Langhorne
Journal:  Immunobiology       Date:  1989-10       Impact factor: 3.144

8.  Monoclonal antibodies against murine gamma interferon.

Authors:  M Prat; G Gribaudo; P M Comoglio; G Cavallo; S Landolfo
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

9.  Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes.

Authors:  P Scott; P Caspar; A Sher
Journal:  J Immunol       Date:  1990-02-01       Impact factor: 5.422

10.  Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract.

Authors:  P Scott; E Pearce; P Natovitz; A Sher
Journal:  J Immunol       Date:  1987-11-01       Impact factor: 5.422

View more
  9 in total

1.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Glycyrrhizic acid-mediated subdual of myeloid-derived suppressor cells induces antileishmanial immune responses in a susceptible host.

Authors:  Syamdas Bandyopadhyay; Amrita Bhattacharjee; Sayantan Banerjee; Kuntal Halder; Shibali Das; Bidisha Paul Chowdhury; Subrata Majumdar
Journal:  Infect Immun       Date:  2015-09-08       Impact factor: 3.441

3.  Leishmania chagasi T-cell antigens identified through a double library screen.

Authors:  Daniella R A Martins; Selma M B Jeronimo; John E Donelson; Mary E Wilson
Journal:  Infect Immun       Date:  2006-09-25       Impact factor: 3.441

4.  Ultrastructural and cytochemical identification of megasome in Leishmania (Leishmania) chagasi.

Authors:  Sanny O Alberio; Suzana S Dias; Flávio P Faria; Renato A Mortara; Clara L Barbiéri; Edna Freymüller Haapalainen
Journal:  Parasitol Res       Date:  2004-01-09       Impact factor: 2.289

5.  Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

Authors:  Rhea N Coler; Yasir A W Skeiky; Karen Bernards; Kay Greeson; Darrick Carter; Charisa D Cornellison; Farrokh Modabber; Antonio Campos-Neto; Steven G Reed
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

6.  In situ immunolocalization and stage-dependent expression of a secretory serine protease in Leishmania donovani and its role as a vaccine candidate.

Authors:  Rajdeep Choudhury; Partha Das; Siddhartha Kumar Bhaumik; Tripti De; Tapati Chakraborti
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

7.  Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells.

Authors:  Rhea N Coler; Yasuyuki Goto; Lisa Bogatzki; Vanitha Raman; Steven G Reed
Journal:  Infect Immun       Date:  2007-07-02       Impact factor: 3.441

8.  Mimetic membrane system to carry multiple antigenic proteins from Leishmania amazonensis.

Authors:  Fabiana R Santos; Denise B Ferraz; Katia R P Daghastanli; F Juarez Ramalho-Pinto; Pietro Ciancaglini
Journal:  J Membr Biol       Date:  2006-08-14       Impact factor: 2.426

9.  Vaccination in Leishmaniasis: A Review Article.

Authors:  Latifeh Abdellahi; Fariba Iraji; Anahita Mahmoudabadi; Seyed Hossein Hejazi
Journal:  Iran Biomed J       Date:  2022-01-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.